Blog

Herbert Loong: A Multi-Agent AI-Assisted System Designed for Clinical Trials Matching

Codex Genetics/LinkedIn

Jul 19, 2025, 09:24

Herbert Loong: A Multi-Agent AI-Assisted System Designed for Clinical Trials Matching

Herbert Loong, Chair-Elect of the International Affairs Committee and the Track Leader for Sarcoma (2023) at the American Society of Clinical Oncology (ASCO), shared a post on LinkedIn by Codex Genetics adding:

“Come find us at ESMO TAT Asia25 as we present our work on utilizing the ClinMatch platform – a multi-agent AI assisted LLM system designed for clinical trials matching.

Many thanks to the HKEX Foundation for their generous support!”

Quoting Codex Genetics’s post below:

“Codex Genetics at ESMO TAT Asia Congress 2025. 18 July 2025 | 5:30pm to 6:00pm

Since 2019, Codex Genetics has been collaborating with Prince of Wales Hospital and the Department of Clinical Oncology at The Chinese University of Hong Kong to explore the potential of Artificial Intelligence in advancing precision medicine and AI-assisted clinical trial matching. We are proud to introduce our latest innovation—ClinMatch, a multi-agent LLM system designed to revolutionize patient-trial matching in precision oncology.

ClinMatch leverages the power of Large Language Models (LLM) to analyze unstructured and incomplete patient clinical records, optimizing them for efficient clinical trial matching. Our platform can identify rare subgroups within patient cohorts and significantly reduce the resources and time required for manual patient-trial matching.

Key features:

Enables the parsing of heterogeneous data within unstructured inputs (including support for Simplified Chinese).
Accurately identifies and removes personally identifiable information to protect sensitive patient data.
Easily illustrates the treatment history of patients, helping clinicians understand the effects of treatments across patient cohorts.
Automates clinical trial matching for parsed patient profiles, evaluating each eligibility criterion for precision alignment.

We would like to thank the CUHK Medicine, the Enterprise Support Scheme of the Innovation and Technology Commission, and the Hong Kong Exchanges and Clearing Limited (HKEX) Impact Funding Scheme for their generous support.

Join us as we present our latest findings from 5:30pm to 6:00pm at the ESMO TAT Asia Congress 2025. We look forward to engaging with you, exchanging ideas, and exploring future partnerships.

See you there!”

More posts featuring Herbert Loong.